ten23 health expands excipient options for biologic drug development with an external collaboration

Basel, Switzerland. July 15th, 2026 — ten23 health® today highlights its research collaboration with **dsm-firmenich**, focused on expanding excipient options for parenteral biologic drug products. By combining complementary expertise, the collaboration aims to address one of the longstanding challenges in biologic formulation development: the limited availability of excipients suitable for injectable medicines.

As biologic therapies become increasingly complex, formulation scientists face growing challenges in achieving product stability, manufacturability, and long-term performance. While excipients play a critical role in addressing these challenges, relatively few are available for parenteral biologic applications, limiting formulation flexibility.

Through this collaboration, ten23 health contributes its expertise in formulation development for sterile products, analytical characterization and pharmaceutical manufacturing, while **dsm-firmenich** brings extensive capabilities in pharmaceutical ingredient science, quality systems and regulatory support. Together, the teams are evaluating pharmaceutical-grade ingredients with established safety profiles as potential excipient candidates for biologic formulations.

The research follows a structured scientific approach, including proof-of-concept studies, benchmarking against established excipients and evaluation in representative protein formulations using advanced analytical methods. Initial findings have identified promising candidates, which are currently undergoing further verification and characterization.

"*Our approach has been to identify promising ingredients based on their safety profiles, regulatory acceptance, and suitability for biologic formulations*," said Prof. Dr. Andrea Allmendinger, Chief Scientific Officer at ten23 health. "*Following proof-of-concept studies and advanced analytical evaluation in representative protein formulations, we have generated promising initial data, which is now being further verified*."

When successful, the collaboration could help pharmaceutical developers improve formulation stability, enhance manufacturability and increase flexibility during product development. Expanding excipient options may also contribute to more efficient development processes and support the design of drug products better suited to patient needs, including self-administration and improved usability.

The collaboration reflects a shared commitment by both organizations to advancing biologic drug development through scientific excellence, responsible innovation and cross-disciplinary collaboration.

Read on the collaboration in detail here.

ten23 health® AG
Mattenstrasse 22
4058 Basel
Switzerland

contact@ten23.health
www.ten23.health

About ten23 health

ten23 health®, located in Basel and Visp, Switzerland, and with commercial presence in the USA and offices in Tokyo, Japan, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients.
ten23 health® combines the latest scientific findings with proven and tested world-class industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people's health and the future of our planet. ten23 health® is a B Corp member and solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner.

About the company's name

The numeric value for the number of molecules in a sample of one mol is called Avogadro constant and equals 6.022 * 10^{23}. Gram quantities of material contain the incredible number of 10^{23} atoms, which was an important discovery to understand the composition of matter: The world is built from small units, and not a homogeneous mass.

About 3i Group

3i is an investment company with two complementary businesses, Private Equity and Infrastructure, and invests in mid-market companies headquartered in Europe and North America. 3i's Private Equity team provides investment solutions for growing companies, backing entrepreneurs and management teams of companies with an EV typically between €100m - €500m. 3i backs international growth plans, providing access to its network and expertise to accelerate the growth of companies across the consumer, healthcare, industrial and private label, and services and software industries.

Media contacts:

ten23 health: Mara Willa, mara.willa@ten23.health
3i Group: Kathryn van der Kroft, Kathryn.VanDerKroft@3i.com

ten23 health® AG
Mattenstrasse 22
4058 Basel
Switzerland

contact@ten23.health
www.ten23.health